866-997-4948(US-Canada Toll Free)

Mycosis Fungoides - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : May 2013

Category :

Oncology

No. of Pages : 51 Pages


Global Markets Directs, \'Mycosis Fungoides Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Mycosis Fungoides, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mycosis Fungoides. 

Mycosis Fungoides Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Mycosis Fungoides.
  • A review of the Mycosis Fungoides products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Mycosis Fungoides pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Mycosis Fungoides.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Mycosis Fungoides pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mycosis Fungoides Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Mycosis Fungoides 7
Mycosis Fungoides Therapeutics under Development by Companies 9
Mycosis Fungoides Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Mycosis Fungoides Therapeutics - Products under Development by Companies 14
Mycosis Fungoides Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Mycosis Fungoides Therapeutics Development 16
Shionogi & Co., Ltd. 16
Seattle Genetics, Inc. 17
Spectrum Pharmaceuticals, Inc. 18
Yaupon Therapeutics, Inc. 19
Mycosis Fungoides - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
brentuximab vedotin - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
mechlorethamine hydrochloride - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
[pralatrexate] + [bexarotene] - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Genetically Modified T Cells 1138 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
interferon gamma-1a - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Mycosis Fungoides Therapeutics - Drug Profile Updates 36
Mycosis Fungoides Therapeutics - Discontinued Products 48
Mycosis Fungoides - Product Development Milestones 49
Featured News & Press Releases 49
Jun 05, 2012: Ceptaris Receives Complete Response Letter From FDA For Mechlorethamine Gel 49
Oct 04, 2011: FDA Accepts Filing Of NDA For Yaupongel\'s Gel Formulation Of Mechlorethamine Hydrochloride 49

Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Table


Number of Products Under Development for Mycosis Fungoides, H1 2013 7
Products under Development for Mycosis Fungoides - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
Shionogi & Co., Ltd., H1 2013 16
Seattle Genetics, Inc., H1 2013 17
Spectrum Pharmaceuticals, Inc., H1 2013 18
Yaupon Therapeutics, Inc., H1 2013 19
Assessment by Monotherapy Products, H1 2013 20
Assessment by Combination Products, H1 2013 21
Assessment by Stage and Route of Administration, H1 2013 23
Assessment by Stage and Molecule Type, H1 2013 25
Mycosis Fungoides Therapeutics - Drug Profile Updates 36
Mycosis Fungoides Therapeutics - Discontinued Products 48

List of Chart


Number of Products under Development for Mycosis Fungoides, H1 2013 7
Products under Development for Mycosis Fungoides - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 20
Assessment by Combination Products, H1 2013 21
Assessment by Route of Administration, H1 2013 22
Assessment by Stage and Route of Administration, H1 2013 23
Assessment by Molecule Type, H1 2013 24
Assessment by Stage and Molecule Type, H1 2013 25

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *